Loading patent…
AssigneeGenVec, Inc.
InventorsDouglas E. Brough, Imre Kovesdi
Estimating the term…
The present invention provides a method of modulating the persistence of expression of a transgene in an at least E4Δ adenoviral vector in a cell. In one embodiment, the method comprises contacting the cell with an at least E4Δ adenoviral vector comprising (i) a transgene and (ii) a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. In another embodiment, the method comprises contacting the cell simultaneously or sequentially with (i) an at least E4Δ adenoviral vector comprising a transgene and (ii) a viral vector comprising a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. In addition, the present invention provides a recombinant at least E4Δ adenoviral vector for use in the method and a composition comprising the vector and a carrier therefor. Also provided by the present invention is a system for modulation of a recombinant at least E4Δ adenoviral vector for use in the method and a composition comprising the system and a carrier therefor.
A method of modulating the persistence of expression of a transgene in an at least E4Δ adenoviral vector in a cell, which method comprises contacting the cell with an at least E4Δ adenoviral vector comprising (i) a transgene and (ii) a gene encoding a trans-acting factor, wherein said trans-acting factor modulates the persistence of expression of the transgene and wherein said gene encoding a trans-acting factor is not from the E4 region of an adenovirus.
A method of modulating the persistence of expression of a transgene in an at least E4Δ adenoviral vector in a cell, which method comprises contacting the cell simultaneously or sequentially with (i) an at least E4Δ adenoviral vector comprising a transgene and (ii) a viral vector comprising a gene encoding a trans-acting factor, wherein said trans-acting factor modulates the persistence of expression of the transgene and wherein said gene encoding a trans-acting factor is not from the E4 region of an adenovirus.
A recombinant at least E4Δ adenoviral vector comprising (i) a transgene and (ii) a gene encoding a trans-acting factor, wherein said trans-acting factor modulates the persistence of expression of the transgene and wherein said gene encoding a trans-acting factor is not from the E4 region of an adenovirus.
A system for modulation of a recombinant at least E4Δ adenoviral vector comprising (i) an at least E4Δ adenoviral vector comprising a transgene and (ii) a viral vector comprising a gene encoding a trans-acting factor, wherein said trans-acting factor modulates the persistence of expression of the transgene and wherein said gene encoding a trans-acting factor is not from the E4 region of an adenovirus.
The system of claim 61, wherein said MAR is selected from the group consisting of murine immunoglobulin heavy chain μ, human apolipoprotein B, human papillomavirus type 16, and human clotting factor VIII and said SAR is human β-interferon.
Dependencies are inferred from the claim text.